SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 18, 2004
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
10275 SCIENCE CENTER DRIVE,
SAN DIEGO, CALIFORNIA
(Address of principal executive offices)
(858) 550-7500 (Registrant's telephone number, including
area code)
77-0160744
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
Item 5. Other Events
On March 16, 2004, Paul V. Maier, our Senior Vice President and Chief
Financial Officer, entered into a stock selling plan, intended to qualify for
the safe harbor under Rule 10b5-1 under the Securities Exchange Act of 1934, as
amended. Under the plan, Mr. Maier authorized the sale of up to 24,938 shares
that were acquired on August 21, 2002 when he exercised an option granted by the
Company.
Mr. Maier has informed the Company that any sales pursuant to this plan
will comply with Rule 144. Mr. Maier has represented to the Company that he had
no knowledge of any material nonpublic information regarding the Company when he
adopted the plan.
Any actual sales under the plan will be publicly disclosed under Rule
16a-3.
Item 7. Exhibits
EXHIBIT NUMBER DESCRIPTION
99.1 Trading Plan for Paul V. Maier dated March 16, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the undersigned.
LIGAND PHARMACEUTICALS INCORPORATED
Date : March 18, 2004 By: /S/WARNER BROADDUS
Name: Warner Broaddus
Title: Vice President,
General Counsel & Secretary